Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Expenses (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Operating Expenses readings, the most recent being $22.0 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 3.73% to $22.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $90.2 million, a 3.15% decrease, with the full-year FY2025 number at $90.2 million, down 3.15% from a year prior.
  • Operating Expenses hit $22.0 million in Q4 2025 for Aligos Therapeutics, down from $29.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $38.3 million in Q4 2021 to a low of $19.5 million in Q2 2025.
  • Median Operating Expenses over the past 5 years was $26.1 million (2022), compared with a mean of $26.6 million.
  • Biggest five-year swings in Operating Expenses: plummeted 33.38% in 2022 and later skyrocketed 35.99% in 2025.
  • Aligos Therapeutics' Operating Expenses stood at $38.3 million in 2021, then tumbled by 31.57% to $26.2 million in 2022, then rose by 9.38% to $28.7 million in 2023, then dropped by 26.1% to $21.2 million in 2024, then increased by 3.73% to $22.0 million in 2025.
  • The last three reported values for Operating Expenses were $22.0 million (Q4 2025), $29.1 million (Q3 2025), and $19.5 million (Q2 2025) per Business Quant data.